We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Forced To Review Cholesterol Drug Exclusivity

Law360 (March 16, 2006, 12:00 AM EST) -- Departing from a lower court ruling, the U.S. Court of Appeals for the District of Columbia Circuit has demanded that the U.S. Food and Drug Administration revisit the issue of generic exclusivity, after a contentious decision involving cholesterol drug Pravachol.

On Thursday, the court reversed a federal district court decision that had granted Teva Pharmaceuticals Inc. six months to exclusively market pravastatin, the generic version of Bristol-Myers Squibb Co.’s Pravachol.

Last July, Israel-based Teva sued the FDA over an earlier decision that effectively wiped out this...
To view the full article, register now.